NanoZolid®-formulated Docetaxel is Safe and Tolerable Showing Signs of Clinical Efficacy
UPPSALA, SWEDEN – LIDDS AB (publ) announced today that no further patients will be enrolled in its dose escalating Phase I study (NZ-DTX-001) with the primary objective to study safety of NanoZolid®-docetaxel in solid tumors. The data collected in the trial demonstrates safety and tolerability, an active and local drug release of docetaxel over an extended period of time and signs of clinical effect in injected tumors.LIDDS plan to communicate the topline results from the study in Q4 2021.
“We have reached an important milestone with the final enrollment of patients in the NZ-DTX-001 study. Preliminary assessments and observations indicate good safety and tolerability in patients treated intratumorally with NanoZolid®-docetaxel. After proper closing of the study, we intend to communicate next step forward for the program” said Nina Herne, CEO of LIDDS.
The clinical Phase I trial NZ-DTX-001 aims to examine whether NanoZolid® in combination with docetaxel, one of the most commonly used drugs for cytostatic treatment of breast, prostate, head, neck, stomach and lung cancer, is safe and tolerable. A secondary objective is to assess efficacy on tumor response.
About the NZ-DTX-001 Phase I study
NZ-DTX-001 is a Phase Ia/Ib, first-in-human, open label, multicenter, dose-escalation and dose-expansion study of a novel NanoZolid®-docetaxel depot formulation (NZ-DTX) given as an intratumoral injection in patients with advanced solid tumors. The NZ-DTX-001 study is a multi-center study including Karolinska University Hospital in Sweden, Herlev Hospital in Denmark, Kaunas University Hospital and Vilnius National Cancer Institute in Lithuania.
For more information, please contact:
Nina Herne, CEO, +46 (0)70 714 7457, e-mail: nina.herne@liddspharma.com
LIDDS is required to disclose the information pursuant to the EU Market Abuse Regulation and the Swedish Securities Markets Act (2007:258). The information was submitted for publication, through the agency of the aforementioned contact, on 4 October 2021 at 19.30 CET.
LIDDS AB (publ) is a Swedish-based pharmaceutical company focusing on a unique proprietary drug delivery technology: NanoZolid®. NanoZolid® is a clinically validated drug development technology and superior in its ability to provide a controlled and sustained release of active drug substances for up to six months. LIDDS has licensing agreements where NanoZolid® is combined with antiandrogens and in-house development projects in clinical and preclinical phase for cytostatics and immunoactive agents. LIDDS shares are listed on Nasdaq First North Growth Market (ticker LIDDS). Redeye AB is the Certified Adviser to LIDDS (+46 (0) 8 121 576 90, email: certifiedadviser@redeye.se) For more information, please visit www.liddspharma.com
Attachment
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Azerion continues expansion in the Nordics by acquiring 26% of Eniro26.4.2024 19:57:10 CEST | Press release
Amsterdam, 26 April 2024 - Azerion announces today a strategic investment in Eniro Group AB (“Eniro”) executed through the purchase of approximately 26% of its ordinary shares. This is another important step in executing Azerion’s strategy to build one of Europe’s largest digital advertising platforms, integrating networks of digital audiences, publishing and advertising technology. As part of the strategic partnership, Azerion will acquire the shares in Eniro from its two largest current shareholders, SpectrumOne AB and B.O. Intressenter AB, who both will retain a significant shareholding in Eniro and ongoing interest in the future commercial collaboration between Eniro and Azerion. Separately, Azerion and Eniro are intending to enter into commercial agreements across a wide range of products and services strengthening their combined presence in the Nordic markets and underlying Azerion's commitment to partnering with local market leaders. This collaboration aims to offer new digital
NGS Group AB: NGS Groups företrädesemission övertecknad enligt preliminärt utfall26.4.2024 18:20:00 CEST | Pressemelding
Teckningsperioden i NGS Group AB:s (publ) (”NGS Group” eller ”Bolaget”) nyemission av aktier med företrädesrätt för befintliga aktieägare om ca 35,2 MSEK, före emissionskostnader (”Företrädesemissionen”) som beslutades av styrelsen den 29 februari 2024 och godkändes av den extra bolagsstämman den 26 mars 2024, avslutades idag den 26 april 2024. Det preliminära utfallet indikerar att teckningar och anmälningar om teckning med och utan stöd av teckningsrätter har erhållits motsvarande totalt cirka 145,6 procent av Företrädesemissionen. Slutligt utfall i Företrädesemissionen väntas offentliggöras genom pressmeddelande den 29 april 2024. Preliminärt utfall i Företrädesemissionen Teckningsperioden i Företrädesemissionen löpte fram till och med den 26 april 2024 och den preliminära sammanställningen visar att cirka 10 188 504 aktier, motsvarande cirka 94,1 procent av Företrädesemissionen tecknats med stöd av teckningsrätter. Därtill har teckningsanmälningar om cirka 5 570 754 aktier, motsvar
Millicom (Tigo) notice of first quarter 2024 results and video conference26.4.2024 18:13:53 CEST | Press release
Millicom (Tigo) notice of first quarter 2024 results and video conference Luxembourg, April 26, 2024 – Millicom expects to announce its first quarter 2024 results on May 8, 2024, via a press release. Millicom is planning to host a video conference for the global financial community on May 8, 2024, at 14:00 (Stockholm) / 13:00 (London) / 08:00 (Miami). Registration for the interactive event is required at the following link. After registering, you will receive a confirmation email containing details about joining the video conference. Participants who wish to ask a question during the live event must notify the Investor Relations team via email to investors@millicom.com after the start of the event. Participants may also join the conference in listen-only mode by dialing any of the following numbers and entering the Webinar ID: 822 3803 6738: US: +1 929 205 6099 Sweden: +46 850 539 728 UK: +44 330 088 5830 Luxembourg: +352 342 080 9265 Additional international numbers are available at t
Fly Play hf.: Ólafur Þór has decided to resign26.4.2024 18:03:00 CEST | Press release
Ólafur Þór Jóhannesson has decided to resign as Chief of Finance at PLAY airlines. Ólafur will remain as CFO at the company until his successor arrives. „Ólafur has been a great team member at PLAY. He was instrumental during the capital raise in Q1 and now leaves the company in a strong position. I wish Ólafur all the best in his upcoming ventures,“ says Einar Örn Ólafsson, CEO of PLAY. „I am truly grateful to have gotten the chance to be a part of this PLAY journey. After a successful capital raise, I feel it is the right time for me to step aside and turn my attention to other ventures. I would like to use this opportunity to wish PLAY and my colleagues all the best and I look forward to see the company take the next steps into a bright future,“ says Ólafur Þór Jóhannesson.
Implementation of new long-term share-based incentive programme26.4.2024 17:59:37 CEST | Press release
The board of directors of Svitzer Group A/S (the “Board of Directors”), CVR-no. 44791447, (“Svitzer Group” or the “Company”) has today decided to implement a new long-term share based incentive programme consisting of restricted share units (“RSUs”) for 2024 (the "LTI") and to implement an extraordinary share-based incentive programme in the form of one-off grants of RSUs related to completion of the demerger and separate listing of the Company ( “Extraordinary RSUs”) and grant a cash completion bonus to the members of the executive management and other eligible employees as also described in the prospectus published by Svitzer A/S on 22 March 2024. Long-term share-based incentive programme for 2024 The LTI for 2024 is share-based and designed to incentivise long-term performance, commitment, and retention of the members of the executive management and other eligible employees, as well as to promote alignment of their interests with those of the shareholders. Under the LTI for 2024, th